Evidence map›Paper›PMID 40547027›Full record

ArticleFrontiers in immunology2025

The N-6 methyladenosine dynamics in STEMI and the effect of IL-6 inhibition - a hypothesis generating sub-study of the ASSAIL-MI trial.

Tuva B Dahl, Ana Quiles-Jiménez, Kaspar Broch, Anne Kristine Anstensrud, Lars Gullestad, Geir Ø Andersen, Ola Kleveland, Jonas Øgaard, Vigdis Bjerkeli, Azita Rashidi and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tuva B DahlResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Ana Quiles-JiménezResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Kaspar BrochDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Anne Kristine AnstensrudDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Lars GullestadDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Geir Ø AndersenDepartment of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.
Ola KlevelandClinic of Cardiology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Jonas ØgaardResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Vigdis BjerkeliResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Azita RashidiResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Kuan YangResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Kirsten B HolvenDepartment of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
Pål AukrustResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Magnar BjøråsDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Camilla Huse *Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Bente Halvorsen *Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Epitranscriptomics, with m Methods: In this explorative sub-study of the ASSAIL-MI trial, we used whole blood samples from patients with acute ST-elevation MI (STEMI) (n=6) at admission and after 3-7 days, and from healthy control subjects (n=3). RNA was isolated, and m Results: Compared with controls, patients with STEMI had a strikingly different pattern of m Conclusions: In this hypothesis generating study, m

Indexed as

AdenosineInterleukin-6 InhibitorsST Elevation Myocardial InfarctionAgedFemaleHumansInterleukin-6MaleMiddle AgedRNA, MessengerAdenosineIL6 protein, humanInterleukin-6Interleukin-6 InhibitorsN-methyladenosineRNA, MessengerepitranscriptomeinflammationN6-methyladenosine (m6A)RNA methylationSTEMItocilizumab

Identifiers

PMID40547027
PMCPMC12178860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.